Virus therapy targets superbug in transplant patients
NCT ID NCT06938867
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment called SNIPR001, which uses specially designed viruses to kill a type of antibiotic-resistant E. coli bacteria. The trial includes 24 adults with blood cancer who are scheduled for a stem cell transplant and already carry these resistant bacteria. Participants will receive either SNIPR001 or a placebo alongside standard antibiotics to see if it is safe and can reduce the bacteria.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SNIPR001 (a mixture of viruses that target E. coli bacteria)
What this could lead to
If it works, this could help prevent dangerous E. coli infections in stem cell transplant patients who carry resistant bacteria.
What could go wrong
This is a very early, small trial with only 24 participants. The treatment may not work or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
John Hopkins University
RECRUITINGBaltimore, Maryland, 21218, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UPMC
RECRUITINGPittsburgh, Pennsylvania, 15213-2582, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94118, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Weill Cornell Medicine
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••